Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 1
1996 1
1997 1
2000 2
2001 1
2002 1
2005 1
2006 1
2010 1
2012 2
2013 1
2014 2
2015 1
2016 3
2017 1
2018 3
2019 5
2020 2
2021 1
2022 5
2023 7
2024 8
2025 5
2026 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

55 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean B. verbruggen (96 results)?
Liberal fluid intake versus fluid restriction in chronic heart failure: a randomized clinical trial.
Herrmann JJ, Brunner-La Rocca HP, Baltussen LEHJM, Beckers-Wesche F, Bekkers SCAM, Bellersen L, van Eck JWM, Hassing HC, Jaarsma T, Linssen GCM, Pisters R, Sanders-van Wijk S, Verdijk MHI, Handoko ML, van der Meer P, Verbrugge FH, Januzzi JL Jr, Bayés-Genís A, Nieuwlaat R, Rodwell L, Gommans DHF, van Kimmenade RRJ. Herrmann JJ, et al. Nat Med. 2025 Jun;31(6):2062-2068. doi: 10.1038/s41591-025-03628-4. Epub 2025 Mar 30. Nat Med. 2025. PMID: 40159556 Free article. Clinical Trial.
Acetazolamide in Acute Decompensated Heart Failure with Volume Overload.
Mullens W, Dauw J, Martens P, Verbrugge FH, Nijst P, Meekers E, Tartaglia K, Chenot F, Moubayed S, Dierckx R, Blouard P, Troisfontaines P, Derthoo D, Smolders W, Bruckers L, Droogne W, Ter Maaten JM, Damman K, Lassus J, Mebazaa A, Filippatos G, Ruschitzka F, Dupont M; ADVOR Study Group. Mullens W, et al. N Engl J Med. 2022 Sep 29;387(13):1185-1195. doi: 10.1056/NEJMoa2203094. Epub 2022 Aug 27. N Engl J Med. 2022. PMID: 36027559 Clinical Trial.
METHODS: In this multicenter, parallel-group, double-blind, randomized, placebo-controlled trial, we assigned patients with acute decompensated heart failure, clinical signs of volume overload (i.e., edema, pleural effusion, or ascites), and an N-terminal pro-B-type natriu …
METHODS: In this multicenter, parallel-group, double-blind, randomized, placebo-controlled trial, we assigned patients with acute decompensa …
Parkinson's disease variant detection and disclosure: PD GENEration, a North American study.
Cook L, Verbrugge J, Schwantes-An TH, Schulze J, Foroud T, Hall A, Marder KS, Mata IF, Mencacci NE, Nance MA, Schwarzschild MA, Simuni T, Bressman S, Wills AM, Fernandez HH, Litvan I, Lyons KE, Shill HA, Singer C, Tropea TF, Vanegas Arroyave N, Carbonell J, Cruz Vicioso R, Katus L, Quinn JF, Hodges PD, Meng Y, Strom SP, Blauwendraat C, Lohmann K, Casaceli C, Rao SC, Ghosh Galvelis K, Naito A, Beck JC, Alcalay RN. Cook L, et al. Brain. 2024 Aug 1;147(8):2668-2679. doi: 10.1093/brain/awae142. Brain. 2024. PMID: 39074992 Free PMC article.
Angiotensin Receptor Neprilysin Inhibitor in Heart Failure With Preserved Ejection Fraction and Secondary Mitral Regurgitation: The PRAISE-MR Randomized Trial.
Dhont S, Moura Ferreira S, Galloo X, Martens P, Meekers E, Tartaglia K, Deferm S, Herbots L, Mullens W, Verbrugge FH, Verwerft J, Bertrand PB. Dhont S, et al. Circulation. 2026 Jun 23;153(25):1973-1983. doi: 10.1161/CIRCULATIONAHA.126.080833. Epub 2026 May 9. Circulation. 2026. PMID: 42104906 Clinical Trial.
Secondary outcomes included changes in peak oxygen consumption (peak VO(2)), Kansas City Cardiomyopathy Questionnaire (KCCQ), N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels, left atrial (LA) volume and function, and AFMR severity in rest and during stress. .. …
Secondary outcomes included changes in peak oxygen consumption (peak VO(2)), Kansas City Cardiomyopathy Questionnaire (KCCQ), N-terminal pro …
Proteasome inhibitors as experimental therapeutics of autoimmune diseases.
Verbrugge SE, Scheper RJ, Lems WF, de Gruijl TD, Jansen G. Verbrugge SE, et al. Arthritis Res Ther. 2015 Jan 28;17(1):17. doi: 10.1186/s13075-015-0529-1. Arthritis Res Ther. 2015. PMID: 25889583 Free PMC article. Review.
The antiproliferative capacity of proteasome inhibitors (PIs) has received considerable attention given the success of their first prototypical representative, bortezomib (BTZ), in the treatment of B cell and plasma cell-related hematological malignancies. Therapeutic appl …
The antiproliferative capacity of proteasome inhibitors (PIs) has received considerable attention given the success of their first prototypi …
Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelodysplastic syndromes: the HOVON89 trial.
van de Loosdrecht AA, Cremers EMP, Alhan C, Duetz C, In 't Hout FEM, Visser-Wisselaar HA, Chitu DA, Verbrugge A, Cunha SM, Ossenkoppele GJ, Janssen JJWM, Klein SK, Vellenga E, Huls GA, Muus P, Langemeijer SMC, de Greef GE, Te Boekhorst PAW, Raaijmakers MHG, van Marwijk Kooy M, Legdeur MC, Wegman JJ, Deenik W, de Weerdt O, van Maanen-Lamme TM, Jobse P, van Kampen RJW, Beeker A, Wijermans PW, Biemond BJ, Tanis BC, van Esser JWJ, Schaar CG, Noordzij-Nooteboom HS, Jacobs EMG, de Graaf AO, Jongen-Lavrencic M, Stevens-Kroef MJPL, Westers TM, Jansen JH. van de Loosdrecht AA, et al. Leukemia. 2024 Apr;38(4):840-850. doi: 10.1038/s41375-024-02161-6. Epub 2024 Jan 31. Leukemia. 2024. PMID: 38297135 Free PMC article. Clinical Trial.
A randomized phase-II study was performed in low/int-1 risk MDS (IPSS) to study efficacy and safety of lenalidomide without (arm A) or with (arm B) ESA/G-CSF. In arm B, patients without erythroid response (HI-E) after 4 cycles received ESA; G-CSF was added if no HI- …
A randomized phase-II study was performed in low/int-1 risk MDS (IPSS) to study efficacy and safety of lenalidomide without (arm A) or with …
Exercise Echocardiography for Risk Stratification in Unexplained Dyspnea: The Incremental Value of the Mean Pulmonary Artery Pressure/Slope.
Falter M, Bekhuis Y, L'Hoyes W, Milani M, Hoedemakers S, Soens L, Moura-Ferreira S, Dhont S, Pauwels R, Jacobs A, De Schutter S, Delpire B, Verbeeck J, Stassen J, Gevaert AB, Debonnaire P, Van de Bruaene A, Bertrand PB, Herbots L, Jasaityte R, Verbrugge FH, Claessen G, Verwerft J. Falter M, et al. J Am Soc Echocardiogr. 2025 Oct;38(10):875-889. doi: 10.1016/j.echo.2025.06.007. Epub 2025 Jun 20. J Am Soc Echocardiogr. 2025. PMID: 40545060
The mPAP/CO slope remained independently prognostic after adjustment for N-terminal pro-B-type natriuretic peptide (hazard ratio [HR], 2.26; 95% CI, 1.33-3.82) and for HFpEF scores and diastolic stress testing (HR, 1.99; 95% CI, 1.37-2.88), whereas exercise tricuspid regur …
The mPAP/CO slope remained independently prognostic after adjustment for N-terminal pro-B-type natriuretic peptide (hazard ratio [HR] …
55 results